-
LTGO share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of LTGO shares has increased $1.63 since the market last closed. This is a 7.22% rise.
-
Opened at $22.64.
The stock opened $0.07 higher than its previous close.
Key terms
About LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
-
Market cap: $1.43B
A market capitalization between $300 million and $2 billion places LTGO in the small capitalization category.
Key terms
Smart score
Latest LTGO news
LTGO Financials
-
LTGO total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
LTGO net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
LTGO earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
LTGO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LTGO Competitors
-
How competitors are chosen
LTGO's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $1.43B
A market capitalization between $300 million and $2 billion places LTGO in the small capitalization category.
Key terms
Latest investing news
-
Bond market takes a breather after surprise move by Treasury Department -
Global bond markets are getting hammered. Here’s why that could make your life more expensive -
‘Brazen act of self-dealing.’ Lawmakers, watchdogs alarmed after Trump regulators let Trump firm start a bank -
The S&P 500 is back at a record high and the Dow just hit 54,000
